129 related articles for article (PubMed ID: 37776305)
21. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of flow cytometry in detection of minimal residual disease in cerebrospinal fluid.
Luo Y; Lin T; Xian L; Zhao Y; Li W; Liu J; Lan M; Shan H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1838-1843. PubMed ID: 38448377
[TBL] [Abstract][Full Text] [Related]
23. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
[TBL] [Abstract][Full Text] [Related]
24. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible.
Dworzak MN; Gaipa G; Ratei R; Veltroni M; Schumich A; Maglia O; Karawajew L; Benetello A; Pötschger U; Husak Z; Gadner H; Biondi A; Ludwig WD; Basso G
Cytometry B Clin Cytom; 2008 Nov; 74(6):331-40. PubMed ID: 18548617
[TBL] [Abstract][Full Text] [Related]
25. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
26. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia.
Liu X; Zou Y; Chen X; Wang S; Guo Y; Yang W; Zhang L; Chen Y; Zhang Y; Zhu X
Leuk Lymphoma; 2020 Dec; 61(14):3460-3467. PubMed ID: 32779947
[TBL] [Abstract][Full Text] [Related]
28. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
29. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
Baraka A; Sherief LM; Kamal NM; Shorbagy SE
Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
[TBL] [Abstract][Full Text] [Related]
30. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
[TBL] [Abstract][Full Text] [Related]
31. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
[TBL] [Abstract][Full Text] [Related]
32. [Characteristics and monitoring of minimal residual disease in patients with T acute lymphoid leukemia by flow cytometry with two 4-color combinations of fluorescent antibodies].
Li L; Yuan XJ; Xu C; Jiang LM; Shen LS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1103-9. PubMed ID: 23114128
[TBL] [Abstract][Full Text] [Related]
33. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction.
Cheng SH; Lau KM; Li CK; Chan NP; Ip RK; Cheng CK; Lee V; Shing MM; Leung AW; Ha SY; Cheuk DK; Lee AC; Li CH; Luk CW; Ling SC; Hrusak O; Mejstrikova E; Leung Y; Ng MH
PLoS One; 2013; 8(7):e69467. PubMed ID: 23936021
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.
Dworzak MN; Fröschl G; Printz D; Mann G; Pötschger U; Mühlegger N; Fritsch G; Gadner H;
Blood; 2002 Mar; 99(6):1952-8. PubMed ID: 11877265
[TBL] [Abstract][Full Text] [Related]
36. Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
Vinhas E; Lucena-Silva N; Pedrosa F
Cytometry B Clin Cytom; 2018 Jan; 94(1):94-99. PubMed ID: 27342632
[TBL] [Abstract][Full Text] [Related]
37. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
Wang H; Zhou Y; Huang X; Zhang Y; Qian J; Li J; Li C; Li X; Lou Y; Zhu Q; Huang Y; Meng H; Yu W; Tong H; Jin J; Zhu HH
Br J Haematol; 2021 Jun; 193(6):1096-1104. PubMed ID: 33764511
[TBL] [Abstract][Full Text] [Related]
39. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
[TBL] [Abstract][Full Text] [Related]
40. Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.
Modvig S; Hallböök H; Madsen HO; Siitonen S; Rosthøj S; Tierens A; Juvonen V; Osnes LTN; Vålerhaugen H; Hultdin M; Matuzeviciene R; Stoskus M; Marincevic M; Lilleorg A; Ehinger M; Norén-Nystrøm U; Toft N; Taskinen M; Jónsson OG; Pruunsild K; Vaitkeviciene G; Vettenranta K; Lund B; Abrahamsson J; Porwit A; Schmiegelow K; Marquart HV
Leukemia; 2021 Jul; 35(7):1894-1906. PubMed ID: 33318611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
